Menu
Search
|

Menu

Close
X

Horizon Pharma PLC HZNP.OQ (NASDAQ Stock Exchange Global Select Market)

21.06 USD
-1.16 (-5.22%)
As of 5:42 PM GMT
chart
Previous Close 22.22
Open 22.02
Volume 187,369
3m Avg Volume 450,725
Today’s High 22.19
Today’s Low 21.01
52 Week High 23.37
52 Week Low 12.58
Shares Outstanding (mil) 163.35
Market Capitalization (mil) 2,211.82
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.18 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY18
852
FY17
1,056
FY16
981
FY15
757
EPS (USD)
FY18
-1.004
FY17
-2.976
FY16
-1.038
FY15
0.212
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
2.15
5.69
Price to Book (MRQ)
vs sector
2.15
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
183.94
15.71
LT Debt to Equity (MRQ)
vs sector
183.12
11.53
Return on Investment (TTM)
vs sector
-13.86
15.05
Return on Equity (TTM)
vs sector
-36.88
16.62

EXECUTIVE LEADERSHIP

Timothy Walbert
Chairman of the Board, President, Chief Executive Officer, Since 2010
Salary: $1,033,330.00
Bonus: $1,167,650.00
Paul Hoelscher
Chief Financial Officer, Executive Vice President, Since 2014
Salary: $541,667.00
Bonus: $319,110.00
Irina Konstantinovsky
Chief Human Resource Officer, Executive Vice President, Since 2017
Salary: $147,538.00
Bonus: $70,471.00
Barry Moze
Executive Vice President, Chief Administrative Officer, Since 2017
Salary: $571,667.00
Bonus: $334,195.00
Shao-Lee Lin
Executive Vice President, Head of Research and Development, Chief Scientific Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

1st Fl, Burleigh Mews, 1 Burling
DUBLIN     HM 09

Phone: +3531.7722100

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

SPONSORED STORIES